IBD Unclassified.
Plain-language, evidence-based information about IBD unclassified (IBD-U) and indeterminate colitis — when inflammatory bowel disease is clearly present but can't yet be labeled ulcerative colitis or Crohn's.
Mostly continuous — UC-like
Rectum usually involved
Backwash ileitis may occur
Focal full-thickness ulcers
Perianal disease may occur
Distinguishing features
IBD-U shows overlapping features of ulcerative colitis and Crohn's, without the granulomas or deep ulcers that define Crohn's — the label often clarifies over time.
| Feature | UC | IBD-U | Crohn's |
|---|---|---|---|
| Clinical | |||
| Distribution | Continuous | Mostly continuous | Skip lesions |
| Rectum | Involved | Usually involved | Often spared |
| Backwash ileitis | May occur | May occur | Crohn's ileitis |
| Perianal disease | Absent | May be present | Characteristic |
| Pathology | |||
| Inflammation depth | Mucosal | Mucosal | Transmural |
| Ulcers | Superficial | Focal full-thickness* | Deep, fissuring |
| Granulomas | Absent | Absent | May be present |
* In IBD-U, focal full-thickness ulcers are seen mainly in severe or fulminant colitis. Backwash ileitis: mild inflammation of the terminal ileum (the last part of the small bowel) spilling back from an inflamed cecum. Granulomas: organized clusters of immune cells on biopsy that, when present, point to Crohn's. IBD-U shows overlapping features without granulomas — the label often clarifies over time.
Frequently Asked Questions
Quick, plain-language answers to the questions we hear most.
What does "IBD unclassified" mean?
It means you clearly have inflammatory bowel disease limited to the colon, but the tests can't yet decide whether it's ulcerative colitis or Crohn's. It's a recognized, valid diagnosis used for about 10–15% of people with colonic IBD. 1–3
Is IBD-U a separate, third disease?
No. It's genuine IBD of the colon — only the UC-versus-Crohn's label is uncertain. It is not milder or more serious by definition; the severity depends on your own inflammation. 4–6
Is IBD-U the same as indeterminate colitis?
They're closely related. 'Indeterminate colitis' is the term pathologists use for a removed colon that shows overlapping features. 'IBD unclassified' is the clinical term used before or without surgery. People often use them interchangeably. 10,11
Will my diagnosis ever become clear?
Often, yes. For many people the picture clarifies over time — new findings, the disease course, or the response to treatment eventually point to UC or Crohn's. For others it remains unclassified, and that's okay. 12,13
How is IBD-U treated?
Day-to-day treatment follows the same principles as colitis — 5-ASAs, steroids for flares, immunomodulators, and biologics, chosen by how active the disease is. The label matters most when surgery is being considered. 23,25
Why does the UC-versus-Crohn's label matter for surgery?
If the colon needs to be removed, the type of reconstruction — and the chance of a successful J-pouch — depends partly on whether the disease behaves more like UC or Crohn's. That's why the label is revisited over time. 26–28
Can I still get a J-pouch (IPAA)?
Many people with IBD-U do well with an ileal pouch. Because Crohn's affects pouch outcomes, the decision is individualized with your surgeon, and outcomes generally fall between those of UC and Crohn's. 29–31
Why does IBD-unclassified complicate the decision to have a J-pouch (IPAA)?
A J-pouch is the standard restorative option for ulcerative colitis, but it fares worse in Crohn's disease, where fistulas and pouch inflammation are more common and pouch failure is higher. When the diagnosis is IBD-unclassified, the surgical team is effectively betting on which disease will declare itself later. Many centers still offer a pouch in IBD-unclassified with careful counseling, since a substantial share of patients behave like ulcerative colitis.
Is IBD-U related to PSC or perianal disease?
Some people with IBD also develop primary sclerosing cholangitis (PSC) — a chronic bile-duct disease that co-occurs with IBD and raises the long-term risk of colorectal cancer 34,35 — or perianal disease. These are separate features that can occur alongside any IBD subtype, including IBD-U. If PSC is part of your picture, see our sister site IBD-PSC.org; for perianal Crohn's, see pCrohns.org.
Why the Label Is Sometimes Unclear
Diagnosing UC versus Crohn's relies on the pattern of inflammation seen at colonoscopy, on biopsies, on imaging, and over time. 14–16 When these don't line up cleanly, the honest answer is "IBD unclassified."
Overlapping features
UC typically affects the colon continuously from the rectum; Crohn's is often patchy and can involve the small bowel. IBD-U is diagnosed when the colon-only findings mix these patterns. 17,18
The full workup
Colonoscopy with biopsies, small-bowel imaging, and sometimes blood/stool markers all contribute. No single test settles it — it's the whole picture. 19–21
Provider resources — IBD-U evidence digest
IBDunclassified.org is written for patients; this section is the clinician-facing companion — a concise, evidence-anchored primer on IBD-unclassified (IBD-U) and indeterminate colitis (IC) for trainees and non-specialist providers. Every reference below has been verified against PubMed and links to its record. Note: most pouch-outcome data are IC-specific; IBD-U has a thinner dedicated evidence base. Surgery and pouch-outcome evidence is under Treatment. For the surgical evidence hub see Crohnsology.org; for the family overview see IBDology.org.
Classification & terminology
IBD-U (a clinical label for colitis that is neither clearly ulcerative colitis nor Crohn's after full workup) is distinct from indeterminate colitis (a pathological term applied to colectomy specimens). The Montreal framework standardised IBD phenotyping.
- Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19 Suppl A:5A-36A. PMID 16151544
- Mitchell PJ, Rabau MY, Haboubi NY. Indeterminate colitis. Tech Coloproctol. 2007;11(2):91-6. PMID 17510748
Diagnosis & serology
Serological markers (pANCA/ASCA) have limited discriminatory value in isolation; paediatric diagnosis follows the revised Porto criteria.
- Levine A, Koletzko S, Turner D, et al. ESPGHAN revised Porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr. 2014;58(6):795-806. PMID 24231644
- Mokrowiecka A, Daniel P, Slomka M, et al. Clinical utility of serological markers in inflammatory bowel disease. Hepatogastroenterology. 2009;56(89):162-6. PMID 19453050
Reclassification over time
A substantial share of IBD-U/IC is reclassified to UC or Crohn's over follow-up; serologic status and longitudinal course inform, but do not fully predict, the eventual diagnosis.
- Joossens S, Reinisch W, Vermeire S, et al. The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology. 2002;122(5):1242-7. PMID 11984510
- Henriksen M, Jahnsen J, Lygren I, et al. Change of diagnosis during the first five years after onset of inflammatory bowel disease: results of a prospective follow-up study (the IBSEN Study). Scand J Gastroenterol. 2006;41(9):1037-43. PMID 16938716
- Winter DA, Karolewska-Bochenek K, Lazowska-Przeorek I, et al. Pediatric IBD-unclassified is less common than previously reported: results of an 8-year audit of the EUROKIDS Registry. Inflamm Bowel Dis. 2015;21(9):2145-53. PMID 26164665
- Wands DIF, Gianolio L, Cameron F, et al. Pediatric inflammatory bowel disease type unclassified: a nationwide cohort study in Scotland with up to 20 years follow-up shows reclassification in the majority. Inflamm Bowel Dis. 2025;31(2):313-20. PMID 39321100
Paediatric natural history
- Abraham BP, Mehta S, El-Serag HB. Natural history of pediatric-onset inflammatory bowel disease: a systematic review. J Clin Gastroenterol. 2012;46(7):581-9. PMID 22772738
This digest is educational and does not replace clinical judgement or society guidelines.
How IBD-U Is Managed
Day-to-day medical treatment of IBD-U follows the same principles as colitis: control inflammation, reach remission, and keep it. 23,25 The bigger reason the label matters is surgery — especially decisions about the J-pouch (IPAA).
Medical therapy
The same families of medicines used for colitis — including 5-ASAs, steroids for flares, immunomodulators, and biologics — are used in IBD-U, guided by how active the disease is. 13,23
When surgery is considered
If the colon needs to be removed, the choice of reconstruction depends partly on whether the disease behaves more like UC or Crohn's, because Crohn's affects pouch outcomes. 26–28
IBD-U and the J-pouch
Many people with IBD-U do well with an ileal pouch (IPAA). Outcomes are generally between those of UC and Crohn's, so the decision is individualized with your surgeon. 29–31
Shared decisions
Because the label can evolve, surgical planning is a careful, shared conversation — sometimes staged — to keep the best options open. 31–33
Provider resources — management & surgery
The clinician-facing companion to the treatment overview above — evidence on medical management and on ileal pouch-anal anastomosis (IPAA) outcomes under diagnostic uncertainty. Every reference is verified against PubMed and links to its record. Note: most pouch-outcome data are indeterminate-colitis (IC)-specific; IBD-U has a thinner dedicated evidence base. For the surgical evidence hub see Crohnsology.org.
Medical therapy
Day-to-day medical management of IBD-U/IC follows colitis principles — 5-ASAs, corticosteroids for flares, immunomodulators, and biologics titrated to disease activity; the label matters most at the point of surgical decision-making.
- Venkateswaran N, Weismiller S, Clarke K. Indeterminate colitis — update on treatment options. J Inflamm Res. 2021;14:6383-6395. PMID 34876831
Surgery & pouch outcomes
Ileal pouch-anal anastomosis outcomes in indeterminate colitis are generally acceptable but carry a higher rate of Crohn's-like complications and pouch failure than UC; counselling and consent should reflect this uncertainty.
- Emile SH, Gilshtein H, Wexner SD. Outcome of ileal pouch-anal anastomosis in patients with indeterminate colitis: a systematic review and meta-analysis. J Crohns Colitis. 2020;14(7):1010-20. PMID 31912129
- Delaney CP, Remzi FH, Gramlich T, Dadvand B, Fazio VW. Equivalent function, quality of life and pouch survival rates after ileal pouch-anal anastomosis for indeterminate and ulcerative colitis. Ann Surg. 2002;236(1):43-8. PMID 12131084
- Murrell ZA, Melmed GY, Ippoliti A, et al. A prospective evaluation of the long-term outcome of ileal pouch-anal anastomosis in patients with inflammatory bowel disease-unclassified and indeterminate colitis. Dis Colon Rectum. 2009;52(5):872-8. PMID 19502850
- Netz U, Galbraith NJ, O'Brien S, et al. Long-term outcomes following ileal pouch-anal anastomosis in patients with indeterminate colitis. Surgery. 2018;163(3):535-41. PMID 29325789
This digest is educational and does not replace clinical judgement or society guidelines. Surgical decision-making under diagnostic uncertainty is covered in depth on Crohnsology.org.
Explore the IBD-Unclassified Research
About IBDunclassified.org
IBDunclassified.org is a plain-language, evidence-based guide to IBD unclassified (IBD-U) and indeterminate colitis — what the diagnosis means, how it is made, how it is managed, and what it means for surgery. When disease does not fit neatly into ulcerative colitis or Crohn's, clear information is scarce and the relevant evidence can take ~17 years to reach routine care; this site closes that gap by pairing the best available IBD-U literature with a “deep and narrow” AI that answers questions in plain language. It is one of the patient-facing sites in the IBDology family.
This site was created by Stefan D. Holubar, MD, MS, FACS, FASCRS, Professor of Surgery at Cleveland Clinic and the Cleveland Clinic Lerner College of Medicine & Case Western Reserve University. A fellowship-trained colorectal surgeon who specializes in inflammatory bowel disease—and, living with IBD and a J-pouch himself, a patient too—he brings both perspectives to this work. He is co-PI of the Crohn's & Colitis Foundation IBD-SIRCQ and the ACS-NSQIP IBD Collaborative, founder of the iPouch Consortium, and has authored over 300 peer-reviewed publications.
Dr. Holubar is an employee of Cleveland Clinic, and has the following disclosures: research funding from the American Society of Colon & Rectal Surgeons and the Crohn's & Colitis Foundation, and has no other disclosures or conflicts of interest.